BR9504230A - Composto composiçao farmacêutica método para o tratamento ou prevençao de uma doença e utilizaçao de um composto - Google Patents

Composto composiçao farmacêutica método para o tratamento ou prevençao de uma doença e utilizaçao de um composto

Info

Publication number
BR9504230A
BR9504230A BR9504230A BR9504230A BR9504230A BR 9504230 A BR9504230 A BR 9504230A BR 9504230 A BR9504230 A BR 9504230A BR 9504230 A BR9504230 A BR 9504230A BR 9504230 A BR9504230 A BR 9504230A
Authority
BR
Brazil
Prior art keywords
compound
pct
treatment
disease
prevention
Prior art date
Application number
BR9504230A
Other languages
English (en)
Inventor
Kishor A Desai
Anton F J Fliri
Mark A Sanner
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of BR9504230A publication Critical patent/BR9504230A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BR9504230A 1994-09-30 1995-09-29 Composto composiçao farmacêutica método para o tratamento ou prevençao de uma doença e utilizaçao de um composto BR9504230A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31547094A 1994-09-30 1994-09-30

Publications (1)

Publication Number Publication Date
BR9504230A true BR9504230A (pt) 1996-08-06

Family

ID=23224581

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9504230A BR9504230A (pt) 1994-09-30 1995-09-29 Composto composiçao farmacêutica método para o tratamento ou prevençao de uma doença e utilizaçao de um composto

Country Status (34)

Country Link
US (1) US5852031A (pt)
EP (1) EP0783503B1 (pt)
JP (1) JP3287574B2 (pt)
KR (1) KR100244848B1 (pt)
CN (1) CN1068327C (pt)
AT (1) ATE209648T1 (pt)
AU (1) AU681310B2 (pt)
BR (1) BR9504230A (pt)
CA (1) CA2200959C (pt)
CO (1) CO4410335A1 (pt)
CZ (1) CZ285090B6 (pt)
DE (1) DE69524241T2 (pt)
DK (1) DK0783503T3 (pt)
ES (1) ES2166830T3 (pt)
FI (1) FI113655B (pt)
HR (1) HRP950507B1 (pt)
HU (1) HUT77354A (pt)
IL (1) IL115384A (pt)
MX (1) MX9702350A (pt)
MY (1) MY113729A (pt)
NO (1) NO308995B1 (pt)
NZ (1) NZ290936A (pt)
PE (1) PE47196A1 (pt)
PL (1) PL180899B1 (pt)
PT (1) PT783503E (pt)
RU (1) RU2163239C2 (pt)
SI (1) SI9520096A (pt)
SK (1) SK284341B6 (pt)
TR (1) TR199501194A2 (pt)
TW (1) TW406081B (pt)
UA (1) UA50720C2 (pt)
WO (1) WO1996010571A1 (pt)
YU (1) YU63795A (pt)
ZA (1) ZA958223B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6231833B1 (en) * 1999-08-05 2001-05-15 Pfizer Inc 2,7-substituted octahydro-1H-pyrido[1,2-A]pyrazine derivatives as ligands for serotonin receptors
US6992188B1 (en) 1995-12-08 2006-01-31 Pfizer, Inc. Substituted heterocyclic derivatives
JP3204456B2 (ja) * 1995-12-21 2001-09-04 ファイザー・インコーポレーテッド ２，７―置換オクタヒドロ―ピロロ［１，２―ａ］ピラジン誘導体
US6281216B1 (en) * 1998-02-09 2001-08-28 Duphar International Research B.V. 2-aminoquinoline derivatives having d4-agonistic activity
EP0953567A3 (en) * 1998-04-29 2003-04-02 Pfizer Products Inc. Bicyclic substituted piperazine-, piperidine- and tetrahydropyridine derivatives, their preparation and their use as agents with central dopaminergic (dopamine D4 receptor) activity
GT199900060A (es) * 1998-05-22 2000-10-14 Polimorfos de un monoclorhidrato de pirazina cristalino y sus composiciones farmacèuticas.
GB0010757D0 (en) 2000-05-05 2000-06-28 Astrazeneca Ab Chemical compounds
GB0011013D0 (en) * 2000-05-09 2000-06-28 Astrazeneca Ab Chemical compounds
EP1177792A3 (en) * 2000-07-27 2002-10-23 Pfizer Products Inc. Dopamine D4 Ligands for the treatment of novelty-seeking disorders
US6670476B2 (en) 2000-11-29 2003-12-30 Pfizer Inc. Resolution of trans-7-(hydroxy-methyl)octa-hydro-2H-pyrido[1,2-a]pyrazine
GB0121941D0 (en) 2001-09-11 2001-10-31 Astrazeneca Ab Chemical compounds

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3388128A (en) * 1965-09-03 1968-06-11 Allan R. Day Substituted 1, 4-diazabicyclo [4. 4. 9] decanes
US4182763A (en) * 1978-05-22 1980-01-08 Mead Johnson & Company Buspirone anti-anxiety method
US4517187A (en) * 1982-10-18 1985-05-14 Pennwalt Corporation 1,3,4,6,7-11b-Hexahydro-7-phenyl-2H-pyrazino[2,1-a]isoquinolines methods of preparation, and use as antidepressants
DE3564683D1 (en) * 1984-08-07 1988-10-06 Cortial 4-(arylpiperazinylethylaminoethoxy) phenol derivatives, process for their preparation and their therapeutical application
US4704390A (en) * 1986-02-13 1987-11-03 Warner-Lambert Company Phenyl and heterocyclic tetrahydropyridyl alkoxy-benzheterocyclic compounds as antipsychotic agents
IT1204803B (it) * 1986-02-17 1989-03-10 Acraf Composto farmacologicamente attivo e composizioni farmaceutiche che lo contengono,procedimento per prepararlo e intermedio utile in detto procedimento
US4788290A (en) * 1987-12-11 1988-11-29 American Home Products Corporation Serotonergic pyrazine derivatives
SE8803429D0 (sv) * 1988-09-28 1988-09-28 Pharmacia Ab Novel pyridyl- and pyrimidyl derivatives
WO1990008148A1 (en) * 1989-01-23 1990-07-26 Pfizer Inc. Bis-aza-bicyclic anxiolytic agents
ES2072141T3 (es) * 1991-01-31 1995-07-01 Pfizer Resolucion de trans-2-(2-pirimidinil)-7-(hidroximetil)octahidro-2h-pirido(1,2a)pirazina.
US5157034A (en) * 1991-02-27 1992-10-20 Pfizer Inc. Neuroleptic perhydro-1H-pyrido[1,2-a]pyrazines
US5185449A (en) * 1991-02-27 1993-02-09 Pfizer Inc. Process and intermediate for certain bis-aza-bicyclic anxiolytic agents
CA2195622C (en) * 1991-02-27 1999-08-17 Frank J. Urban Process for preparing trans-piperidine-2,5-dicarboxylates
EP0607163B1 (en) * 1991-09-25 1996-12-11 Pfizer Inc. NEUROLEPTIC 2-SUBSTITUTED PERHYDRO-1-H-PYRIDO[1,2-a]PYRAZINES
JP2753146B2 (ja) * 1992-06-16 1998-05-18 ファイザー・インコーポレーテッド ビス−アザー二環式抗不安薬の製法および中間体
ES2133416T3 (es) * 1992-10-23 1999-09-16 Merck Sharp & Dohme Ligandos de subtipos de receptores de dopamina.
JPH08502958A (ja) * 1992-10-23 1996-04-02 メルク シヤープ エンド ドーム リミテツド ドーパミンレセプターサブタイプリガンド
EP0687267B1 (en) * 1993-03-01 1999-09-01 MERCK SHARP & DOHME LTD. Pyrrolo-pyridine derivatives as ligands of dopamine receptor
US5576319A (en) * 1993-03-01 1996-11-19 Merck, Sharp & Dohme Ltd. Pyrrolo-pyridine derivatives
PL310443A1 (en) * 1993-03-01 1995-12-11 Merck Sharp & Dohme Derivatives of pyrolo-pyridine
JPH08508466A (ja) * 1993-03-05 1996-09-10 メルク シヤープ エンド ドーム リミテツド ドーパミンｄ４リガンドとしてのキノロン誘導体
GB9416162D0 (en) * 1994-08-10 1994-09-28 Merck Sharp & Dohme Therapeutic agents

Also Published As

Publication number Publication date
DK0783503T3 (da) 2002-02-11
RU2163239C2 (ru) 2001-02-20
MX9702350A (es) 1997-06-28
PL319636A1 (en) 1997-08-18
EP0783503B1 (en) 2001-11-28
NO308995B1 (no) 2000-11-27
DE69524241T2 (de) 2002-06-13
PL180899B1 (pl) 2001-04-30
AU681310B2 (en) 1997-08-21
JP3287574B2 (ja) 2002-06-04
TR199501194A2 (tr) 1996-06-21
HUT77354A (hu) 1998-03-30
NO971416L (no) 1997-05-20
JPH09511527A (ja) 1997-11-18
FI971310A0 (fi) 1997-03-27
SI9520096A (sl) 1998-04-30
US5852031A (en) 1998-12-22
CN1168672A (zh) 1997-12-24
ZA958223B (en) 1997-04-01
YU63795A (sh) 1999-03-04
SK284341B6 (sk) 2005-02-04
IL115384A0 (en) 1995-12-31
KR100244848B1 (ko) 2000-03-02
CN1068327C (zh) 2001-07-11
UA50720C2 (uk) 2002-11-15
IL115384A (en) 1999-10-28
NZ290936A (en) 1998-01-26
ATE209648T1 (de) 2001-12-15
NO971416D0 (no) 1997-03-25
CA2200959A1 (en) 1996-04-11
HRP950507B1 (en) 2002-06-30
PE47196A1 (es) 1996-11-11
FI113655B (fi) 2004-05-31
HRP950507A2 (en) 1997-08-31
CZ285090B6 (cs) 1999-05-12
DE69524241D1 (de) 2002-01-10
EP0783503A1 (en) 1997-07-16
CZ94797A3 (cs) 1998-07-15
KR970706282A (ko) 1997-11-03
SK32597A3 (en) 1998-09-09
WO1996010571A1 (en) 1996-04-11
TW406081B (en) 2000-09-21
CA2200959C (en) 2000-05-23
ES2166830T3 (es) 2002-05-01
AU3189395A (en) 1996-04-26
MY113729A (en) 2002-05-31
FI971310A (fi) 1997-03-27
CO4410335A1 (es) 1997-01-09
PT783503E (pt) 2002-03-28

Similar Documents

Publication Publication Date Title
MX9307885A (es) Aplicacion de la carbamzaepina y oxcarbazepian para la obtencion de medicamentos para el tratamiento de la enfermedad de parkinson y los sindromes parkinsonianos.
MX9307062A (es) Derivado de quinuclidina para el tratamiento de los trastornos inflamatorios y del sistema nervioso central.
PL309348A1 (en) Application of an agent called riluzole in therapy of neurological damages caused by or associated with injuries
BR9504230A (pt) Composto composiçao farmacêutica método para o tratamento ou prevençao de uma doença e utilizaçao de um composto
FI964482A (fi) Amidijohdannaisia ja niiden käyttö lääkkeenä
DK671588D0 (da) Bisphenylalkylpiperazinderivater og fremgangsmaade til fremstilling deraf
DK0609336T3 (da) Anvendelse af prostacyclin-derivater til forebyggelse eller behandling af lidelser i mikrocirkulationssystemet ved administ
AU655958B2 (en) Use of quisqualate-receptor antagonists for treating Parkinson's disease
ES2119454T3 (es) Derivados de pirrolidina para el tratamiento de los desordenes relacionados con la csk y la gastrina.
ZA9427B (en) Use of riluzole for promoting restoration following radiation

Legal Events

Date Code Title Description
FB36 Technical and formal requirements: requirement - article 36 of industrial property law
FB36 Technical and formal requirements: requirement - article 36 of industrial property law
HJEG Technical examination (opinion): technical examination (opinion) related to article 229 of industrial property law
FG9A Patent or certificate of addition granted
B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 19A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2273 DE 29-07-2014 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.